Intraoperative 32P high-dose rate brachytherapy of the dura for recurrent primary and metastatic intracranial and spinal tumors Journal Article


Authors: Folkert, M. R.; Bilsky, M. H.; Cohen, G. N.; Zaider, M.; Dauer, L. T.; Cox, B. W.; Boland, P. J.; Laufer, I.; Yamada, Y.
Article Title: Intraoperative 32P high-dose rate brachytherapy of the dura for recurrent primary and metastatic intracranial and spinal tumors
Abstract: BACKGROUND: Treatment of spinal and intracranial tumors with dural involvement is complicated by radiation tolerance of sensitive structures, especially in the setting of previous treatment. OBJECTIVE: To evaluate whether intraoperative brachytherapy with short-range sources allows therapeutic dose delivery without damaging sensitive structures. METHODS: The median doses of previous treatment were 3000 cGy (range, 1800-7200 cGy) for 8 patients with primary/recurrent and 17 patients with metastatic spinal tumors and 5040 cGy (range, 1300-6040 cGy) for 5 patients with locally recurrent and 2 patients with metastatic intracranial tumors. Patients underwent gross total or maximal resection of the tumor and were then treated with an intraoperative brachytherapy plaque consisting of a flexible silicone film incorporating P. A dose of 1000 cGy was delivered to a depth of 1 mm; the percent depth dose was less than 1% at 4 mm from the prescription depth. Median postoperative radiation doses of 2700 cGy (range, 1800-3000 cGy) were delivered to 15 spinal tumor patients and 3000 cGy (range, 1800-3000 cGy) to 3 intracranial tumor patients. The median follow-up was 4.4 months (range, 2.6-23.3 months) for spinal tumor patients and 5.3 months (range, 0.7-16.2) for intracranial tumor patients. RESULTS: At 6-month follow-up, for all spinal tumor patients, local progression-free survival and overall survival rates were both 83.3% (95% confidence interval [CI]: 62.3%-94.3%); for all intracranial tumor patients, the local progression-free survival rate was 62.5% (95% CI: 23.8%-90.9%) and the overall survival rate was 66.7% (95% CI: 26.7%-92.9%). There were no intraoperative or postoperative complications secondary to radiotherapy. CONCLUSION: Use of the P brachytherapy plaque is technically simple and not associated with increased risk of complications, even after multiple radiation courses. Local control rates were more than 80% in patients with proven radiation-resistant spinal disease. Copyright © 2012 by the Congress of Neurological Surgeons.
Keywords: metastasis; spine; brachytherapy; recurrent; intraoperative; intracranial; dura
Journal Title: Neurosurgery
Volume: 71
Issue: 5
ISSN: 0148-396X
Publisher: Wolters Kluwer  
Date Published: 2012-11-01
Start Page: 1003
End Page: 1010
Language: English
DOI: 10.1227/NEU.0b013e31826d5ac1
PROVIDER: scopus
PUBMED: 22902332
DOI/URL:
Notes: --- - "Export Date: 3 December 2012" - "CODEN: NRSRD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Brett Wayne Cox
    63 Cox
  2. Patrick J Boland
    160 Boland
  3. Yoshiya Yamada
    479 Yamada
  4. Mark H Bilsky
    319 Bilsky
  5. Michael Ryan Folkert
    36 Folkert
  6. Gilad N Cohen
    180 Cohen
  7. Lawrence Dauer
    170 Dauer
  8. Marco Zaider
    171 Zaider
  9. Ilya Laufer
    146 Laufer